

International Vaccine Design Center

Division of Immunology and Genomics (New Dimensional Vaccine Design Team) 新次元ワクチンデザイン系・ゲノム免疫学分野

Professor Ken Ishii, M.D., Ph.D.
Visiting professor Anavaj Sakuntabhai, M.D., Ph.D.

教授 博士(医学) 石井 健
客員教授 博士(医学) サクンタパイ アナヴァジ

This division has been collaborating with Pasteur Institute in Paris, France via Prof. James DiSanto and Prf. Anavaj Sakuntabhai based on MOU between IMSUT and Pasteur Institute. In FY 2024, Pasteur International Unit on Mucosal Immunomics led by Ken Ishii and James Di Santo together with Prof Sakuntabhai conducted the research and developoment on immunology and genomics on infectious diseases and cancer. The team also contributed to the establishment of Institute Pasteur Japon (IPJ)

Pasteur Japan SCIENTIFIC WORKSHOP were held June 24 2024 at The French Embassy, Tokyo. Objective was to discuss scientific direction/strategy of Institut Pasteur du Japon with scientists in Japan. Scientific discussion was conducted by Yasmine Belkaid, President, Institut Pasteur and moderated by James Di-Santo

Immunology and vaccine/drug design was chaired by James Di Santo and Ken Ishii

James Di Santo, Institut Pasteur described PIU at IMSUT, AMED-SCARDA – the UTOPIA project. Followingly Dr. Cevayir Coban, U of Tokyo presented “Interactions between host and pathogens at the barriers”, Dr. Niloufar Kavian, U of Tokyo presented

“Beyond the Spike: SARS-CoV-2 antibody landscape in adults and children, and its relevance for sero-surveillance in a pandemic era”, Prof. Noriko Sorimachi, U of Tokyo presented “ Developing a research platform for the next pandemic and promoting drug discovery in academia”, and Prof. Ken J. Ishii presented “Science and design of vaccine/adjuvant as nanoparticles”. In the session for Emerging Infectious Diseases

Chaired by Prof. Anavaj Sakuntabhai and Prof. Fumihiko Matsuda, Prof. Anavaj Sakuntabhai presented “PICREID and AMED-ASPIRE”, Prof. Kei Sato, U of Tokyo presented “SARS-CoV-2”. These discussion led to the establishment of various projects between U Tokyo and PI.

Publication

- Iijima N, Yamaguchi M, Hayashi T, Rui Y, Ohira Y, Miyamoto Y, Niino M, Okuno T, Suzuki O, Oka M, [Ishii KJ](#). miR-147-3p in pathogenic CD4 T cells controls chemokine receptor expression for the development of experimental autoimmune diseases. *J Autoimmun.* 2024 Dec;149:103319.
- Ueda T, Adachi T, Hayashi T, Yasuda K, Matsushita K, Koike E, Yanagisawa R, Nagatake T, Kunisawa J, [Ishii KJ](#), Tsuzuki K, Kuroda E. Bisphenol A triggers activation of ocular immune system and aggravates allergic airway inflammation. *Clin Immunol.* 2024 Nov;268:110370.
- Yaku H, Takahashi K, Okada H, Kobiyama K, Shiokawa M, Uza N, Kodama Y, [Ishii KJ](#), Seno H.

- Near-infrared photoimmunotherapy as a complementary modality to in situ vaccine in a preclinical pancreatic cancer model. *Biochem Biophys Res Commun*. 2024 Dec 10;737:150534.
4. Iijima N, Hayashi T, Niino M, Miyamoto Y, Oka M, Ishii KJ. Tridecylcyclohexane in incomplete Freund's adjuvant is a critical component in inducing experimental autoimmune diseases. *Eur J Immunol*. 2024 Oct;54(10):e2350957.
 5. Alshaweesh J, Dash R, Lee MSJ, Kahyaoglu P, Erci E, Xu M, Matsuo-Dapaah J, Del Rosario Zorrilla C, Aykac K, Ekemen S, Kobiyama K, Ishii KJ, Coban C. MyD88 in osteoclast and osteoblast lineages differentially controls bone remodeling in homeostasis and malaria. *Int Immunol*. 2024 Aug 13;36(9):451-464.
 6. Temizoz B, Shibahara T, Hioki K, Hayashi T, Kobiyama K, Lee MSJ, Surucu N, Sag E, Kumanogoh A, Yamamoto M, Gursel M, Ozen S, Kuroda E, Coban C, Ishii KJ. 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a partial STING agonist, competes for human STING activation. *Front Immunol*. 2024 Mar 12;15:1353336.
 7. Sasaki I, Fukuda-Ohta Y, Nakai C, Wakaki-Nishiyama N, Okamoto C, Okuzaki D, Morita S, Kaji S, Furuta Y, Hemmi H, Kato T, Yamamoto A, Tosuji E, Saitoh SI, Tanaka T, Hoshino K, Fukuda S, Miyake K, Kuroda E, Ishii KJ, Iwawaki T, Furukawa K, Kaisho T. A stress sensor, IRE1 α , is required for bacterial-exotoxin-induced interleukin-1 β production in tissue-resident macrophages. *Cell Rep*. 2024 Apr 23;43(4):113981.
 8. Lee MSJ, Matsuo-Dapaah J, Del Rosario Zorrilla C, Omatsu Y, Nagasawa T, Uemura S, Iwama A, Ishii KJ, Coban C. Acute malaria suppresses the B lymphocytic niche in the bone marrow through the alteration of CXCL12-abundant reticular cells. *Int Immunol*. 2024 Jun 8;36(7):339-352.
 9. Guo Z, Murakami M, Saito K, Kato H, Toriyama M, Tominaga M, Ishii KJ, Fujita F. Integrin $\alpha 5$ regulates motility of human monocyte-derived Langerhans cells during immune response. *Exp Dermatol*. 2024 Mar;33(3):e15021.
 10. Kaku Y, Okumura K, Padilla-Blanco M, Kosugi Y, Uriu K, Hinay AA Jr, Chen L, Planchaisuk A, Kobiyama K, Ishii KJ; Genotype to Phenotype Japan (G2P-Japan) Consortium; Zahradnik J, Ito J, Sato K. Virological characteristics of the SARS-CoV-2 JN.1 variant. *Lancet Infect Dis*. 2024 Feb;24(2):e82.
 11. Palacpac NMQ, Ishii KJ, Arisue N, Tougan T, Horii T. Immune tolerance caused by repeated *P. falciparum* infection against SE36 malaria vaccine candidate antigen and the resulting limited polymorphism. *Parasitol Int*. 2024 Apr;99:102845.
 12. Castro Eiro MD, Hioki K, Li L, Wilmsen MEP, Kiernan CH, Brouwers-Haspels I, van Meurs M, Zhao M, de Wit H, Grashof DGB, van de Werken HJG, Mueller YM, Schliehe C, Temizoz B, Kobiyama K, Ishii KJ, Katsikis PD. TLR9 plus STING Agonist Adjuvant Combination Induces Potent Neopeptide T Cell Immunity and Improves Immune Checkpoint Blockade Efficacy in a Tumor Model. *J Immunol*. 2024 Feb 1;212(3):455-465.
 13. Katsikis PD, Ishii KJ, Schliehe C. Challenges in developing personalized neoantigen cancer vaccines. *Nat Rev Immunol*. 2024 Mar;24(3):213-227.
 14. Roth C, Pitard B, Levillayer L, Lay S, Vo HTM, Cantaert T, Sakuntabhai A. Zika virus T-cell based 704/DNA vaccine promotes protection from Zika virus infection in the absence of neutralizing antibodies. *PLoS Negl Trop Dis*. 2024 Oct 17;18(10):e0012601.
 15. Sene O, Sagne SN, Bob NS, Mhamadi M, Dieng I, Gaye A, Ba H, Dia M, Faye ET, Diop SM, Sall Y, Diop B, Ndiaye M, Loucoubar C, Simon-Lorière E, Sakuntabhai A, Faye O, Sall AA, Diallo D, Dia N, Faye O, Diagne MM, Fall M, Ndione MHD, Barry MA, Fall G. Re-Emergence of Rift Valley Fever Virus Lineage H in Senegal in 2022: In Vitro Characterization and Impact on Its Global Emergence in West Africa. *Viruses*. 2024 Jun 25;16(7):1018.
 16. Yean S, Prasetyo DB, Marcombe S, Hadi UK, Kazim AR, Tiawsirisup S, Chinh VD, Matsuno K, Low VL, Bonnet S, Boulanger N, Lam TT, Abdad MY, Herbreteau V, Chavatte JM, Sum S, Ren T, Sakuntabhai A, Maquart PO, Rakotonirina A, Boyer S. Challenges for ticks and tick-borne diseases research in Southeast Asia: Insight from the first international symposium in Cambodia. *PLoS Negl Trop Dis*. 2024 Jul 10;18(7):e0012269.
 17. Sann S, Heng B, Vo HTM, Arroyo Hornero R, Lay S, Sorn S, Ken S, Ou TP, Laurent D, Yay C, Ly S, Dussart P, Duong V, Sakuntabhai A, Kleinewietfeld M, Cantaert T. Increased frequencies of highly activated regulatory T cells skewed to a T helper 1-like phenotype with reduced suppressive capacity in dengue patients. *mBio*. 2024 Jun 12;15(6):e0006324.
 20. Ngom D, Khoulé A, Faye ET, Sène O, Diop SM, Sagne SN, Diallo MK, Dia M, Barry MA, Diaw Y, Bocoum M, Ndiaye EHM, Sall Y, Diop B, Faye O, Faye O, Diallo M, Simon-Lorière E, Sakuntabhai A, Fall G, Diallo D. Crimean-Congo haemorrhagic fever outbreak in Northern Senegal in 2022: Prevalence of the virus in livestock and ticks, associated risk factors and epidemiological implications. *Zoonoses Public Health*. 2024 Sep;71(6):696-707.
 21. Levillayer L, Brighelli C, Demeret C, Sakuntabhai A, Bureau JF. Role of two modules controlling the interaction between SKAP1 and SRC kinases comparison with SKAP2 architecture and consequences for evolution. *PLoS One*. 2024 Mar 14;19(3):e0296230.